As a thought leader in the diagnostic space, and with expertise in diagnostic strategy, launch, commercialization and the patient journey, Diaceutics publishes articles on a variety of topics in dedicated industry journals.
Q&A: Diaceutics’ Jordan Clark on industry, FDA gap on Rx/Dx codevelopment principles
The impact of genetic biomarkers on drug and companion diagnostic return on investment
Great expectations for personalized medicine outside oncology
The economics of personalized medicine: commercialization as a driver of return on investment.
Towards a balanced value business model for personalized medicine: an outlook
Preparing the Company for Long-Term Sustainability in a Rapid Changing World
Why PM1.0 will not create radical healthcare change prompting the need for PM2.0
Effective sales and marketing strategies for drugs with companion diagnostics
Mystery Solved! What is the cost to develop and launch a diagnostic?
Laboratories are the forgotten stakeholder: A corporate profile of Labceutics
Using effective partnering for managing the risk of legal liability
The Options for Test Index (OFTi)
The absence of model changing financial incentives
Role of Opportunity To Test index in integrating diagnostics with therapeutics
IP considerations in early biomarker development in PM
Integrating Diagnostics and Therapeutics for targeted Therapies, Part 2
Integrating Diagnostics and Therapeutics for Targeted Therapies, Part 1
Getting Personalized
Fear of Theranostics – Abstract
Driving PM-capturing max NPV and optimal ROI